This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Merck Patent Gmbh, Pfizer Corporation. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3,025 
1 out of 4,489 
Years Active: 2020
Title: Dimitry Serge Antoine Nuyten: Innovator in Cancer Treatment
Introduction
Dimitry Serge Antoine Nuyten is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic agents.
Latest Patents
Nuyten holds a patent for PD-L1 antagonist combination treatments. This patent describes combination therapies that include an antagonist of the Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent. The use of these combination therapies is aimed at improving treatment outcomes for cancer patients.
Career Highlights
Throughout his career, Nuyten has worked with prominent companies in the pharmaceutical industry, including Merck Patent GmbH and Pfizer Corporation. His experience in these organizations has allowed him to develop and refine his expertise in cancer therapies.
Collaborations
Nuyten has collaborated with several professionals in his field, including Glen Ian Andrews and Shihao Chen. These collaborations have contributed to the advancement of his research and the development of innovative treatment options.
Conclusion
Dimitry Serge Antoine Nuyten is a dedicated inventor whose work in cancer treatment has the potential to make a significant impact on patient care. His innovative approaches and collaborations highlight his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile